Heinz Zoller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8040163/publications.pdf

Version: 2024-02-01

135	4,782	87888 38	114465 63
papers	citations	h-index	g-index

143	143	143	6149
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Interleukin-11 drives human and mouse alcohol-related liver disease. Gut, 2023, 72, 168-179.	12.1	13
2	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. Clinical Gastroenterology and Hepatology, 2023, 21, 978-987.e2.	4.4	12
3	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	12.1	28
4	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone, 2022, 154, 116202.	2.9	40
5	The Need to Update Endpoints and Outcome Analysis in the Rapidly Changing Field of Liver Transplantation. Transplantation, 2022, 106, 938-949.	1.0	8
6	Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1009-1019.	3.6	20
7	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
8	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. Annals of Hepatology, 2022, 27, 100683.	1.5	4
9	Synonymous mutation in adenosine triphosphatase copperâ€transporting beta causes enhanced exon skipping in Wilson disease. Hepatology Communications, 2022, 6, 1611-1619.	4.3	6
10	Responseâ€guided longâ€term treatment of chronic hepatitis D patients with bulevirtideâ€”results of a â€œreal worldâ€•study. Alimentary Pharmacology and Therapeutics, 2022, 56, 144-154.	3.7	46
11	EASL Clinical Practice Guidelines on haemochromatosis. Journal of Hepatology, 2022, 77, 479-502.	3.7	49
12	Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study. European Radiology, 2021, 31, 494-503.	4.5	6
13	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the <scp>MNGIE</scp> International Network. Journal of Inherited Metabolic Disease, 2021, 44, 376-387.	3.6	47
14	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. Gut, 2021, 70, 585-594.	12.1	6
15	Performance of different Dixon-based methods for MR liver iron assessment in comparison to a biopsy-validated R2* relaxometry method. European Radiology, 2021, 31, 2252-2262.	4.5	25
16	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	3.7	26
17	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltosideâ€”a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 2256-2273.	2.4	61
18	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149

#	Article	IF	Citations
19	Neurodegeneration in Hepatic and Neurologic Wilsonâ€™s Disease. Hepatology, 2021, 74, 1117-1120.	7.3	6
20	Systemic inflammation as fuel for acute liver injury in COVID-19. Digestive and Liver Disease, 2021, 53, 158-165.	0.9	63
21	Dual proteotoxic stress accelerates liver injury via activation of <scp>p62â€Nrf2</scp>. Journal of Pathology, 2021, 254, 80-91.	4.5	1
22	Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B Mutations. Journal of Clinical Medicine, 2021, 10, 1901.	2.4	4
23	Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World Journal of Gastroenterology, 2021, 27, 2039-2053.	3.3	2
24	Newer formulations of intravenous iron: a review of their chemistry and key safety aspects â€“ hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opinion on Drug Safety, 2021, 20, 757-769.	2.4	39
25	Static cold storage compared with normothermic machine perfusion of the liver and effect on ischaemic-type biliary lesions after transplantation: a propensity score-matched study. British Journal of Surgery, 2021, 108, 1082-1089.	0.3	43
26	DOP89 Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial. Journal of Crohn's and Colitis, 2021, 15, S121-S121.	1.3	1
27	Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease. Gastroenterology, 2021, 160, 2367-2382.e1.	1.3	48
28	MRIâ€Based Iron Phenotyping and Patient Selection for Nextâ€Generation Sequencing of Nonâ€“Homeostatic Iron Regulator Hemochromatosis Genes. Hepatology, 2021, 74, 2424-2435.	7.3	8
29	Expression of MICA in Zero Hour Biopsies Predicts Graft Survival After Liver Transplantation. Frontiers in Immunology, 2021, 12, 606146.	4.8	3
30	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
31	Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis. Journal of Medical Internet Research, 2021, 23, e21656.	4.3	2
32	MR elastography in patients with suspected diffuse liver disease at 1.5T: Intraindividual comparison of gradient-recalled echo versus spin-echo echo-planar imaging sequences and investigation of potential confounding factors. European Journal of Radiology, 2021, 142, 109898.	2.6	7
33	Bone marker response to intravenous iron treatment - an in vitro model. , 2021, 59, .		0
34	Update on the Austrian epidemiology of Hepatitis D Virus (HDV). , 2021, 59, .		0
35	Reassessment of Relevance and Predictive Value of Parameters Indicating Early Graft Dysfunction in Liver Transplantation: AST Is a Weak, but Bilirubin and INR Strong Predictors of Mortality. Frontiers in Surgery, 2021, 8, 693288.	1.4	6
36	Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease. Clinical Chemistry and Laboratory Medicine, 2021, .	2.3	4

#	Article	IF	Citations
37	Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 830-843.	3.7	9
38	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterology Journal, 2021, 9, 1119-1127.	3.8	20
39	Highly Elevated Plasma Î³â€Glutamyltransferase Elevations: A Trait Caused by Î³â€Glutamyltransferase 1 Transmembrane Mutations. Hepatology, 2020, 71, 1124-1127.	7.3	4
40	Hepatitis C virus eradication with directâ€acting antiviral improves insulin resistance. Journal of Viral Hepatitis, 2020, 27, 188-194.	2.0	20
41	Cloak and dagger â€•secondary hemophygocytic lymphohistiocytosis caused by intravenous autoinfection. American Journal of Hematology, 2020, 95, 330-332.	4.1	1
42	Liver stiffness by transient elastography accompanies illness severity in COVID-19. BMJ Open Gastroenterology, 2020, 7, e000445.	2.7	20
43	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
44	Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report. Journal of Medical Case Reports, 2020, 14, 201.	0.8	2
45	Fatty Liver Disease: Metabolic, Genetic, or Both?. Hepatology Communications, 2020, 4, 1239-1241.	4.3	0
46	Evaluation of liver iron overload with R2* relaxometry with versus without fat suppression: both are clinically accurate but there are differences. European Radiology, 2020, 30, 5826-5833.	4.5	5
47	Is Heterozygosity for the Alpha-1 Antitrypsin Risk Allele Piâ^—MZ a Disease Modifier or Genetic Risk Factor?. Gastroenterology, 2020, 159, 433-434.	1.3	2
48	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1619-1627.	2.8	12
49	Hypophosphatemia in children treated with ferric carboxymaltose. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1491-1492.	1.5	11
50	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. JAMA - Journal of the American Medical Association, 2020, 323, 432.	7.4	162
51	Dietary lipids fuel GPX4-restricted enteritis resembling Crohnâ€™s disease. Nature Communications, 2020, 11, 1775.	12.8	143
52	Intravenous iron supplementation therapy. Molecular Aspects of Medicine, 2020, 75, 100862.	6.4	44
53	Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease. Liver International, 2020, 40, 1941-1951.	3.9	10
54	Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?. European Radiology, 2019, 29, 829-837.	4.5	7

#	Article	IF	Citations
55	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology, 2019, 157, 705-719.e18.	1.3	82
56	Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Alimentary Pharmacology and Therapeutics, 2019, 50, 397-406.	3.7	46
57	Reply. Liver Transplantation, 2019, 25, 344-345.	2.4	0
58	Reply. Liver Transplantation, 2019, 25, 1287-1288.	2.4	0
59	The dilemma to diagnose Wilson disease by genetic testing alone. European Journal of Clinical Investigation, 2019, 49, e13147.	3.4	33
60	Iron Matryoshkaâ€"Haemochromatosis nested in Ferroportin Disease?. Liver International, 2019, 39, 1014-1015.	3.9	4
61	Management of patients with chronic hepatitis C failing repeated courses of interferonâ€free direct acting antiviral combination therapy. GastroHep, 2019, 1, 76-83.	0.6	5
62	P723 Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study. Journal of Crohn's and Colitis, 2019, 13, S482-S483.	1.3	0
63	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilsonâ€™s Disease. JHEP Reports, 2019, 1, 2-8.	4.9	13
64	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	4.8	134
65	P6149Coronary computed tomographic angiography (CTA) for risk stratification in the diagnostic triage of patients undergoing liver transplantation (LT): A long-term outcome study. European Heart Journal, 2019, 40, .	2.2	0
66	Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation. Transplantation, 2019, 103, 2506-2514.	1.0	24
67	Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. Hepatology, 2019, 70, 840-850.	7.3	61
68	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. Hepatology, 2019, 69, 1464-1476.	7.3	110
69	Classical and intermediate monocytes scavenge non-transferrin-bound iron and damaged erythrocytes. JCI Insight, 2019, 4, .	5.0	42
70	OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials. Journal of the Endocrine Society, 2019, 3, .	0.2	2
71	Quantification of hepatic liver iron overload with laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). , 2019, 57, .		0
72	Health Related Quality of Life and Healthcare Resource Utilization in chronic HCV patients under the Glecaprevir/Pibrentasvir Regimen: Interim-Analysis of the Austrian CONFIRMATION Study. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0

#	Article	IF	Citations
73	High pre-test likelihood for non-HFE mutations through full exome sequencing in patients with hepatic iron overload. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
74	Heterozygosity for the alphaâ€1â€antitrypsin Z allele in cirrhosis is associated with more advanced disease. Liver Transplantation, 2018, 24, 744-751.	2.4	58
75	A rare case of Epsteinâ€Barr virusâ€associated hepatosplenic smooth muscle tumors after kidney transplantation. Transplant Infectious Disease, 2018, 20, e12860.	1.7	3
76	Longâ€term followâ€up of ribavirinâ€free <scp>DAA</scp>â€based treatment in <scp>HCV</scp> recurrence after orthotopic liver transplantation. Liver International, 2018, 38, 1188-1197.	3.9	8
77	Followâ€up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirinâ€free treatment. Liver International, 2018, 38, 1028-1035.	3.9	51
78	Transferrin as a predictor of survival in cirrhosis. Liver Transplantation, 2018, 24, 343-351.	2.4	27
79	Con: Liver transplantation for expanded criteria malignant diseases. Liver Transplantation, 2018, 24, 104-111.	2.4	18
80	Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time?. Translational Gastroenterology and Hepatology, 2018, 3, 38-38.	3.0	6
81	Quantification of liver iron overload disease with laser ablation inductively coupled plasma mass spectrometry. BMC Medical Imaging, 2018, 18, 51.	2.7	10
82	Impact of patatinâ€like phospholipase domain containing 3 rs738409ÂG/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 48, 451-459.	3.7	26
83	Disease burden of hepatitis C in the Austrian state of Tyrol â€“ Epidemiological data and model analysis to achieve elimination by 2030. PLoS ONE, 2018, 13, e0200750.	2.5	6
84	Liver disease in adults with Î±1â€antitrypsin deficiency. United European Gastroenterology Journal, 2018, 6, 710-718.	3.8	23
85	Monitoring Iron Overload: Relationship between R2* Relaxometry of the Liver and Serum Ferritin under Different Therapies. Journal of Clinical Imaging Science, 2018, 8, 40.	1.1	2
86	CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedemaâ€cholestasis syndrome. Hepatology, 2017, 66, 286-288.	7.3	6
87	R2*-relaxometry of the pancreas in patients with human hemochromatosis protein associated hereditary hemochromatosis. European Journal of Radiology, 2017, 89, 149-155.	2.6	7
88	Blood and Bone Loser. Gastroenterology, 2017, 152, e5-e6.	1.3	20
89	Iron-induced hypophosphatemia. Current Opinion in Nephrology and Hypertension, 2017, 26, 266-275.	2.0	121
90	3D Multiecho Dixon for the Evaluation of Hepatic Iron and Fat in a Clinical Setting. Journal of Magnetic Resonance Imaging, 2017, 46, 793-800.	3.4	40

#	Article	IF	Citations
91	Letter: retreatment of patients with chronic hepatitis C who have failed interferonâ€free combination therapy with direct acting antiâ€virals. Alimentary Pharmacology and Therapeutics, 2017, 45, 373-375.	3.7	4
92	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothÂIII). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.9	111
93	Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. Alimentary Pharmacology and Therapeutics, 2017, 46, 641-643.	3.7	7
94	Hepatocellular carcinoma: when is liver transplantation oncologically futile?. Translational Gastroenterology and Hepatology, 2017, 2, 63-63.	3.0	20
95	Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS ONE, 2016, 11, e0167146.	2.5	68
96	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transplant International, 2016, 29, 999-1007.	1.6	73
97	Excellent postâ€transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver International, 2016, 36, 688-695.	3.9	38
98	Retrospective angiographic study to determine the effect of atherosclerotic stenoses of upstream arteries on the degree of atherosclerosis in distal vascular territories. BMJ Open, 2016, 6, e010704.	1.9	2
99	[68Ga]NODAGA-RGD â€“ Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2005-2013.	6.4	38
100	Pathogenesis, Diagnosis and Treatment of Hemochromatosis. Digestive Diseases, 2016, 34, 364-373.	1.9	15
101	Indications for liver transplantation in adults. Wiener Klinische Wochenschrift, 2016, 128, 679-690.	1.9	39
102	Response to Successful liver transplantation for hepatocellular carcinoma following downâ€staging using sorafenib single therapy by Borentain etÂal.. Liver International, 2016, 36, 1394-1394.	3.9	0
103	Congenital secretory diarrhoea caused by activating germline mutations inGUCY2C. Gut, 2016, 65, 1306-1313.	12.1	74
104	Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism: Clinical and Experimental, 2016, 65, 1151-1160.	3.4	143
105	EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). European Journal of Human Genetics, 2016, 24, 479-495.	2.8	73
106	Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. Pharmaceuticals, 2015, 8, 337-350.	3.8	6
107	Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease. Human Molecular Genetics, 2015, 24, 6254-6263.	2.9	30
108	Should C282Y homozygotes with mild iron overload be treated?. Journal of Hepatology, 2015, 62, 510-511.	3.7	4

#	Article	IF	Citations
109	R2* Relaxometry for the Quantification of Hepatic Iron Overload: Biopsy-Based Calibration and Comparison with the Literature. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2015, 187, 472-479.	1.3	59
110	Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea. Human Molecular Genetics, 2015, 24, 6614-6623.	2.9	111
111	First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis. Liver Transplantation, 2014, 20, 1145-1148.	2.4	9
112	Iron metabolism in transplantation. Transplant International, 2014, 27, 1109-1117.	1.6	32
113	Effects of 24h working on-call on psychoneuroendocrine and oculomotor function: A randomized cross-over trial. Psychoneuroendocrinology, 2014, 47, 221-231.	2.7	22
114	Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1406-1412.	3.8	18
115	Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. European Radiology, 2013, 23, 1643-1649.	4.5	19
116	Patatin-Like Phospholipase Domain-Containing Protein 3 rs738409-G in Recipients of Liver Transplants Is a Risk Factor for Graft Steatosis. Clinical Gastroenterology and Hepatology, 2013, 11, 1667-1672.	4.4	81
117	Interferon-Alpha Therapy in Patients with Hepatitis C Virus Infection Increases Plasma Phenylalanine and the Phenylalanine to Tyrosine Ratio. Journal of Interferon and Cytokine Research, 2012, 32, 216-220.	1.2	28
118	Cystatin <scp>C</scp> is a strong predictor of survival in patients with cirrhosis: is a cystatin <scp>C</scp>â€based MELD better?. Liver International, 2012, 32, 1211-1216.	3.9	25
119	Control of iron metabolism â€“ Lessons from neonatal hemochromatosis. Journal of Hepatology, 2012, 56, 1226-1229.	3.7	30
120	Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells, Molecules, and Diseases, 2012, 48, 233-237.	1.4	33
121	Identification of Mutations in SLC40A1 That Affect Ferroportin Function and Phenotype of Human Ferroportin Iron Overload. Gastroenterology, 2011, 140, 2056-2063.e1.	1.3	57
122	Saccadic latency in hepatic encephalopathy: a pilot study. Metabolic Brain Disease, 2010, 25, 285-295.	2.9	9
123	Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. Hepatology, 2010, 51, NA-NA.	7.3	24
124	Hepcidin messenger RNA expression in human lymphocytes. Immunology, 2010, 130, 217-230.	4.4	59
125	Ferroportin disease: A systematic meta-analysis of clinical and molecular findings. Journal of Hepatology, 2010, 53, 941-949.	3.7	121
126	Diagnosis of Hepatic Iron Overload. Diagnostic Molecular Pathology, 2009, 18, 53-60.	2.1	10

#	Article	IF	Citations
127	Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. British Journal of Haematology, 2009, 144, 789-793.	2.5	49
128	Autocrine formation of hepcidin induces iron retention in human monocytes. Blood, 2008, 111, 2392-2399.	1.4	255
129	Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Human Pathology, 2007, 38, 1057-1064.	2.0	37
130	CFTR gene mutations in pancreatitis: Frequency and clinical manifestations in an Austrian patient cohort. Wiener Klinische Wochenschrift, 2007, 119, 527-533.	1.9	12
131	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV ? focus on pegylated interferon-alpha. International Journal of Nanomedicine, 2006, 1, 399-409.	6.7	3
132	Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology, 2005, 42, 466-472.	7.3	54
133	Hemochromatosis: Genetic Testing and Clinical Practice. Clinical Gastroenterology and Hepatology, 2005, 3, 945-958.	4.4	36
134	Iron supplementation in athletesâ€"first do no harm. Nutrition, 2004, 20, 615-619.	2.4	106
135	Duodenal cytochrome B and hephaestin expression in patients with iron deficiency and hemochromatosis. Gastroenterology, 2003, 125, 746-754.	1.3	50